TCGA-C8-A12Z-01A-11R-A115-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 13
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- NOTCH_SIGNALING+0.380
- CHOLESTEROL_HOMEOSTASIS+0.360
- GLYCOLYSIS+0.360
- MTORC1_SIGNALING+0.360
- G2M_CHECKPOINT+0.340
- ANDROGEN_RESPONSE+0.330
- E2F_TARGETS+0.280
- MYC_TARGETS_V1+0.250
- SPERMATOGENESIS+0.250
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.410
- INTERFERON_ALPHA_RESPONSE-0.370
- INTERFERON_GAMMA_RESPONSE-0.370
- IL6_JAK_STAT3_SIGNALING-0.260
- INFLAMMATORY_RESPONSE-0.220
- COMPLEMENT-0.170
- TNFA_SIGNALING_VIA_NFKB-0.160
- KRAS_SIGNALING_UP-0.120
- IL2_STAT5_SIGNALING-0.110
- MYOGENESIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1XJ-01A-11R-A14M-07 | — | C | 0.836 |
| 2 | TCGA-BT-A20N-01A-11R-A14Y-07 | — | — | 0.799 |
| 3 | BS_GG9W3J9Y | high-grade glioma | — | 0.796 |
| 4 | TCGA-AC-A23H-01A-11R-A157-07 | — | C | 0.792 |
| 5 | TCGA-92-7341-01A-31R-2045-07 | — | cohortSQ2 | 0.789 |
| 6 | SRR8518424 | — | C | 0.783 |
| 7 | MDT-AP-2956 | Med | Medulloblastoma | 0.780 |
| 8 | 97591eeb-89dc-4b70-92d4-2bb70d263098 | — | — | 0.778 |
| 9 | MDT-AP-0592 | Med | Medulloblastoma | 0.777 |
| 10 | TCGA-33-4586-01A-01R-1443-07 | — | cohortSQ2 | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.360 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.160 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |